Study summary · research use only
Probing for peptidic drugs (2-10 kDa) in doping control blood samples
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This method-development study (species not specified, though the context is anti-doping testing in elite sports) describes an approach for detecting bioactive peptides with molecular mass between 2 and 10 kDa in doping-control blood samples, using liquid chromatography coupled to high-resolution mass spectrometry with resolution properties greater than 100,000 full width at half maximum, following mixed-mode solid-phase extraction sample preparation. The authors report co-extraction and analysis of several peptides, including various insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine, and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295, tesamorelin), insulin-like growth factors (long-R3-IGF-I, R3-IGF-I, Des1-3-IGF-I), and mechano growth factors, meeting criteria in World Anti-Doping Agency (WADA) documents (TD2022 MRPL). The method was demonstrated using post-administration samples from treatment with synthetic insulin analogues.
Abstract
Bioactive peptides with a molecular mass between 2 and 10 kDa represent an important class of substances banned in elite sports, which has been recognized with an increasing number and variety of substances by anti-doping organizations. Also, the annually renewed list of prohibited substances of the World Anti-Doping Agency (WADA) explicitly mentions more and more of these peptides, and efficient testing procedures are required. Even under simplified sample preparation conditions, liquid chromatography coupled to high-resolution mass spectrometry (with resolution properties > 100,000 full width at half maximum) offers suitable conditions for this task and can therefore be used as an initial testing procedure. In contrast to urine, blood analysis essentially relies on the detection of intact peptide hormones, and the expected concentrations are commonly higher in blood samples than in urine. This facilitates the analysis, and a generic sample preparation by means of mixed-mode solid-phase extraction could be realized in this study. Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growth factors (long-R3-IGF-I, R3-IGF-I and Des1-3-IGF-I) and mechano growth factors (human MGF and MGF-Goldspink) with criteria that fulfil the requirements of the WADA documents (TD2022 MRPL) for doping controls. The proof of principle was shown by the analysis of post administration samples after treatment with synthetic insulin analogues.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.